Nuvo Pharmaceuticals 

$0.98
1
+$0+0% Monday 19:42

統計

當日最高
-
當日最低
-
52週高點
-
52週低點
-
成交量
-
平均成交量
-
市值
11.15M
本益比
0
股息殖利率
-
股息
-

財報

28Mar預期
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
-1.58
-0.98
-0.39
0.21
預期EPS
0.07
實際EPS
-0.2

財務

-46.21%利潤率
未盈利
2016
2017
2018
2019
2020
2021
54.83M營收
-25.33M淨利

其他人也在關注

此清單是根據在 Stock Events 上追蹤 MRVFF 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Nuvo Pharmaceuticals Inc. provides prescription and non-prescription products for pain, allergy, neurology, and dermatology worldwide. The company operates in three segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. It offers Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial; Cambia, a nonsteroidal anti-inflammatory drug for migraine; Suvexx/Treximet migraine medicine; NeoVisc viscosupplement for knee osteoarthritis; and Resultz/FullMarks/LAUSBUB for head lice infestations. The company also provides Bezalip SR for patients with high cholesterol or high levels of triglycerides; Proferrin, an iron supplement for the prevention and treatment of iron deficiency; Fiorinal 1 and Fiorinal C1 for the relief of tension-type headaches; Viskazide and Visken antihypertensive agents; Collatamp G for surgical implantation during surgery; PegaLAX, a laxative for the treatment of occasional constipation and irregularity; Mutaflor, a probiotic for the management and relief of chronic constipation and associated abdominal pain and cramps; MoviPrep for the cleansing of the colon in preparation for colonoscopy; Uracyst for mild to severe GAG layer damage of the urinary bladder; and Soriatane to treat psoriasis and other keratinization disorders. In addition, it offers Pennsaid and Pennsaid 2% topical treatments for osteoarthritic pain; Vimovo for relief of arthritis symptoms; SYNERA/RAPYDAN topical patches used to help prevent pain associated with needle sticks and other superficial skin procedures; Yosprala for the prevention of heart attacks and strokes; and Heated Lidocaine/Tetracaine Patch, a topical patch applied prior to painful medical procedures. The company was formerly known as Nuvo Research Inc. and changed its name to Nuvo Pharmaceuticals Inc. in March 2016. Nuvo Pharmaceuticals Inc. was founded in 1983 and is headquartered in Mississauga, Canada.
Show more...
執行長
Mr. Jesse F. Ledger
員工
99
國家
CA
ISIN
CA67092F1045
WKN
000A2AD5S

上市

0 Comments

分享你的想法

FAQ

Nuvo Pharmaceuticals 今天的股價是多少?
MRVFF 目前價格為 $0.98 USD,過去 24 小時上漲了 +0%。在圖表上更密切關注 Nuvo Pharmaceuticals 股價表現。
Nuvo Pharmaceuticals 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Nuvo Pharmaceuticals 的股票以代號 MRVFF 進行交易。
Nuvo Pharmaceuticals 的市值是多少?
今天 Nuvo Pharmaceuticals 的市值為 11.15M
Nuvo Pharmaceuticals 上一季度的財報如何?
MRVFF 上一季度的財報為每股 -0.2 USD,預估為 0.07 USD,帶來 -385.71% 的驚喜。下一季度的預估財報為每股 不適用 USD。
Nuvo Pharmaceuticals 去年的營收是多少?
Nuvo Pharmaceuticals 去年的營收為 54.83MUSD。
Nuvo Pharmaceuticals 去年的淨利是多少?
MRVFF 去年的淨收益為 -25.33MUSD。
Nuvo Pharmaceuticals 有多少名員工?
截至 April 03, 2026,公司共有 99 名員工。
Nuvo Pharmaceuticals 位於哪個產業?
Nuvo Pharmaceuticals從事於Healthcare產業。
Nuvo Pharmaceuticals 何時完成拆股?
Nuvo Pharmaceuticals 最近沒有進行任何拆股。
Nuvo Pharmaceuticals 的總部在哪裡?
Nuvo Pharmaceuticals 的總部位於 CA 的 Mississauga。